Yen Tony, Khafaja Mohamad, Lam Nicholas, Crumbacher James, Schrader Ronald, Rask John, Billstrand Mary, Rothfork Jacob, Abbott Christopher C
From the *Departments of Anesthesiology and †Psychiatry, University of New Mexico School of Medicine, Albuquerque, NM; ‡University of New Mexico School of Medicine, Albuquerque, NM and §Clinical and Translational Science Center, University of New Mexico School of Medicine, Albuquerque, NM.
J ECT. 2015 Mar;31(1):20-5. doi: 10.1097/YCT.0000000000000132.
Methohexital, a barbiturate anesthetic commonly used for electroconvulsive therapy (ECT), possesses dose-dependent anticonvulsant properties, and its use can interfere with effective seizure therapy in patients with high seizure thresholds. Ketamine, an N-methyl-d-aspartate antagonist with epileptogenic properties not broadly used for ECT inductions, is a commonly used induction agent for general anesthesia. Recent studies suggest that the use of ketamine is effective in allowing successful ECT treatment in patients with high seizure thresholds without an increase in adverse effects. In this preliminary study, we directly compared the recovery and reorientation times of subjects receiving ketamine and methohexital for ECTs.
Twenty patients were randomized in a crossover design to receive methohexital and ketamine for ECT inductions in alternating fashion in 6 trials. Primary outcome measures were recovery time (voluntary movement, respiratory effort, blood pressure, consciousness, and O2 saturation) and reorientation time. Secondary outcome measures were individual recovery variables, adverse effect occurrence, and seizure duration.
Overall recovery time was not significantly different between the 2 treatment arms (F(1, 17) = 0.72; P = 0.41). Reorientation time was faster in the methohexital arm (F(1, 17) = 9.23; P = 0.007).
Ketamine inductions resulted in higher number of adverse effects, higher subject dropout rates, and a longer reorientation time with respect to methohexital inductions. No significant difference in postanesthesia recovery time was found between the ketamine and methohexital arms. Intolerability to ketamine affected a significant proportion of subjects and suggests that ketamine should remain as an alternative or adjunctive agent for patients with high seizure thresholds.
甲己炔巴比妥是一种常用于电休克治疗(ECT)的巴比妥类麻醉剂,具有剂量依赖性抗惊厥特性,其使用可能会干扰癫痫阈值高的患者的有效癫痫治疗。氯胺酮是一种具有致癫痫特性的N-甲基-D-天冬氨酸拮抗剂,在ECT诱导中未广泛使用,是常用的全身麻醉诱导剂。最近的研究表明,使用氯胺酮可有效使癫痫阈值高的患者成功接受ECT治疗,且不增加不良反应。在这项初步研究中,我们直接比较了接受氯胺酮和甲己炔巴比妥进行ECT的受试者的恢复和定向时间。
20名患者采用交叉设计随机分组,在6次试验中交替接受甲己炔巴比妥和氯胺酮进行ECT诱导。主要结局指标为恢复时间(自主运动、呼吸努力、血压、意识和血氧饱和度)和定向时间。次要结局指标为个体恢复变量、不良反应发生情况和癫痫持续时间。
两个治疗组的总体恢复时间无显著差异(F(1, 17) = 0.72;P = 0.41)。甲己炔巴比妥组的定向时间更快(F(1, 17) = 9.23;P = 0.007)。
与甲己炔巴比妥诱导相比,氯胺酮诱导导致更多的不良反应、更高的受试者退出率和更长的定向时间。氯胺酮组和甲己炔巴比妥组之间在麻醉后恢复时间上未发现显著差异。相当一部分受试者对氯胺酮不耐受,这表明氯胺酮应保留为癫痫阈值高的患者的替代或辅助药物。